Irinotecan Hcl-Trihydraat Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

• Irinotecan is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.
• Metastatic colorectal cancer: improves overall survival when combined with standard chemotherapy regimens.
• Advanced colorectal cancer: provides disease control for patients with unresectable disease.
• Adjuvant therapy for colorectal cancer: reduces the risk of recurrence after surgical resection.

• Irinotecan is a prodrug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage and ultimately tumor cell death.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Nausea and vomiting: may be managed with antiemetics.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: temporary hair loss during treatment.
• Fatigue: generalized tiredness affecting daily activities.
• Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects

• Severe neutropenic infection: febrile neutropenia requiring immediate medical attention.
• Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance.
• Hepatotoxicity: liver enzyme elevations indicating potential liver injury.

• Before initiating therapy, clinicians should assess patient suitability and monitor for known risks.
• Baseline blood counts: obtain complete blood count to detect pre‑existing neutropenia.
• Liver function: evaluate hepatic enzymes as impaired function can increase toxicity.
• Renal function: adjust monitoring in patients with reduced clearance.
• Pregnancy and lactation: avoid use due to unknown safety profile; discuss alternatives.
• Drug interactions: review concomitant medications for potential CYP3A4 modulators.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Irinotecan interacts with several agents that can modify its efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce SN‑38 exposure.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase SN‑38 levels and risk of severe toxicity.
• UGT1A1 inhibitors (e.g., atazanavir): may impair SN‑38 glucuronidation, raising toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): increased bleeding risk due to platelet suppression.
• Other myelosuppressive agents: additive bone‑marrow depression.
• Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea.
• Granulocyte colony‑stimulating factors: may reduce neutropenia duration.
• Herbal supplements (e.g., St. John’s wort): potential CYP3A4 induction.